Research
Hormonal
Tirzepatide (dual GLP-1/GIP agonist) produces superior weight loss compared to semaglutide in patients with type 2 diabetes.
For patients with type 2 diabetes, tirzepatide (5-15 mg weekly) may offer better weight loss (8.5-12.4%) than semaglutide (6.7%). However, it is not yet registered for obesity treatment in Poland, so access may be limited.
GoodSupportsHIGH confidence
In the study-phase 3 trial-SURPASS 2-, in which the effectiveness of tirzepatide was compared with the widely used semaglutide in 1879 individuals with type 2 diabetes, it was proved that tirzepatide was more efficient. After 40 weeks of drug use, the average weight loss for semaglutide (1 mg) was 6.7%, while for tirzepatide, it ranged from 8.5%, 11%, 12.4% depending on the dosage (5, 10, and 15 mg).
Why this rating
Based on a Phase 3 trial (SURPASS 2) cited in the review.
Source
Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland
Barbara Woch et al. · Journal of Education Health and Sport · 2024
DOI 10.12775/jehs.2024.58.004
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg weekly) produces significantly greater weight loss (15.8%) compared to liraglutide (6.4%) in patients without type 2 diabetes.Good
- Orlistat is the least effective registered anti-obesity drug for weight reduction and is associated with significant gastrointestinal side effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →